From Wikipedia, the free encyclopedia
Delgocitinib
Clinical data
Trade namesCorectim
Other namesJTE-052; JTE-052A
ATC code
Legal status
Legal status
  • Rx-only in Japan
Identifiers
  • 3-[(3S,4R)-3-Methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard ( EPA)
Chemical and physical data
FormulaC16H18N6O
Molar mass310.361 g·mol−1
3D model ( JSmol)
  • C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
  • InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
  • Key:LOWWYYZBZNSPDT-ZBEGNZNMSA-N

Delgocitinib (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. [1] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis. [1] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema. [2]

Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases. [3]

Society and culture

In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Anzupgo (delgocitinib), a medicine intended for the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriate. [4] [5] The applicant for this medicinal product is LEO Pharma A/S. [4]

References

  1. ^ a b Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi: 10.1007/s40265-020-01291-2. PMID  32166597. S2CID  212681247.
  2. ^ Park B (August 5, 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.
  3. ^ Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi: 10.3390/microorganisms8111743. PMC  7694787. PMID  33172122.
  4. ^ a b "Anzupgo EPAR". European Medicines Agency. 25 July 2024. Retrieved 25 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024". European Medicines Agency (Press release). 25 July 2024. Retrieved 29 July 2024.
From Wikipedia, the free encyclopedia
Delgocitinib
Clinical data
Trade namesCorectim
Other namesJTE-052; JTE-052A
ATC code
Legal status
Legal status
  • Rx-only in Japan
Identifiers
  • 3-[(3S,4R)-3-Methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard ( EPA)
Chemical and physical data
FormulaC16H18N6O
Molar mass310.361 g·mol−1
3D model ( JSmol)
  • C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
  • InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
  • Key:LOWWYYZBZNSPDT-ZBEGNZNMSA-N

Delgocitinib (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. [1] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis. [1] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema. [2]

Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases. [3]

Society and culture

In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Anzupgo (delgocitinib), a medicine intended for the treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriate. [4] [5] The applicant for this medicinal product is LEO Pharma A/S. [4]

References

  1. ^ a b Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi: 10.1007/s40265-020-01291-2. PMID  32166597. S2CID  212681247.
  2. ^ Park B (August 5, 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.
  3. ^ Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi: 10.3390/microorganisms8111743. PMC  7694787. PMID  33172122.
  4. ^ a b "Anzupgo EPAR". European Medicines Agency. 25 July 2024. Retrieved 25 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. ^ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024". European Medicines Agency (Press release). 25 July 2024. Retrieved 29 July 2024.

Videos

Youtube | Vimeo | Bing

Websites

Google | Yahoo | Bing

Encyclopedia

Google | Yahoo | Bing

Facebook